Takara Holdings Inc. · TSE:2531
Takara — CLSA presentation (February 2008)
14 slides from Takara's conference presentation, Feb 28, 2008
Slide 1: Solid Foundation, Strong Growth Potential
Strategies of Takara Group p1 Solid Foundation, Foundation Strong Growth Potential 確固たる基盤事業と 可能性を広げる成長事業 能性を広げ 成 事業 February 28, 2008 Takara k Holdings ldi Inc. Representative Director, Executive Vice President Tadashi d hi Omiyai Contents p2 I. Corporate Overview II. Strategies of Alcoholic Beverag
Slide 2: Takara Holdings Inc.
Takara Holdings Inc. p3 ■ Established : 1925 ■ Stock Listings : Tokyo, Tokyo Osaka (Code : 2531) ■ Head Office : Kyoto, Japan ■ Company Representative : Hisashi Omiya, President ■ Issued Capital p : 13,226 million yen y ■ Market Capitalization ：135,191 million yen ■ Net sales ：198,535 ：198 535 milli
Slide 3: Takara Group Structure and Business Outline
Takara Group Structure （As of September 30, 2007） p5 Takara Holdings Inc. Corporate Planning, Finance, Public Relations, Investor Relations Share owned 100% 【Mothers listed:4974】 Established : 2006 Share owned 71.00% Share owned 100% Takara Shuzo Takara Bio i Inc. Co., Ltd. Takara Healthcare Inc. sa
Slide 4: Business Outline of Alcoholic Beverages and Seasonings Business
Business Outline of Alcoholic Beverages and Seasonings Business p7 ▼Sales by segment : Takara Shuzo Group （Millions of yen） Oth 12％ Other Domestic Seasonings Categories Market Share Position , 21,100 12％ Shochu Sh h Shochu (＊) 15 2％ 15.2％ １stt 78,000 45％ Ko-Type 31.3％ １st Other Alcoholic Alcoholic S
Slide 5: Takara Group Chronicle
Takara Group Chronicle p9 1842 Sake brewing business launched launched. （Production （P d ti and d sales l off Sake S k started） t t d） 1864 Shochu and Mirin business launched. 1912 Continuous distillated Shochu launched. 1920 Sake k “Sho-Chiku-Bai” h hik i launched. l h d 1925 Takara Shuzo Co., Ltd.
Slide 6: Twenty year Financial Summary
Twenty year Financial Summary p11 Operating income, Net income Move to a holding Net sales （Millions of Yen） company （Millions of Yen） 16,000 Sixth 250,000 Operating income Net income Net sales Medium-term Management Plan 14,000 200,000 12 000 12,000 10,000 150,000 8,000 100,000 6,000 4,000 50,000 2
Slide 7: Domestic business environment of the alcoholic beverage market
Domestic business environment of the alcoholic beverage market(1) p13 ▼ Low L bibirthrate h and d aging i population. l i Source : The National Institute of Population and Social Security Research ・Population of change (Japanese) National Tax Agency now 140 000 140,000 45 0 45.0 （Thousand people） （%
Slide 8: Strategies: Strengthen the profitability, focus on growth
Strategies p15 Strengthen the profitability. profitability Focusing on the growth business area. ① Expanding the high value- value-added product （“Ikkomon （“ ”,“Takara Shochu Jun Ikkomon” Jun”” etc. etc.）） ② Thorough profit management ③ Corporate restructuring Strategies① Expanding the high value- S
Slide 9: Strategies: Thorough profit management and corporate restructuring
Strategies② Thorough profit management Strategies② p17 1. Continuous cost reduction. To seek efficiency through strict monitoring of production and management costs. 2. Strict managing sales promotion expense. To set up a system to allow sales staff to easily see the cost vs. benefit analyses, y , e
Slide 10: Financial Summary
Financial Summary p19 ▼ Steady business performance in late years FY2008(e) : forecast announced Nov.14, 2007 Takara Shuzo Group Net sales l : 166,400 million illi yen (△4.4% y-o-y) 10,000 Operating income : 7,300 million yen 200,000 (+11.1% y-o-y) 150,000 Operating income 8 000 8,000 Net sales 100,
Slide 11: Strategies of Biomedical Business
Ⅲ． Strategies of Biomedical Business p21 Pursuing P i the th research h and dddevelopment l t of ggene medicine ① Licensing the RetroNectin® Method ② Pursuing the clinical developments of gene therapies and cell therapies directly ③ Strengthen the profitability etc. etc Strategies ① Licensing the Re
Slide 12: Pursuing the clinical developments
Strategies ② Pursuing the clinical developments p23 ▼Clinical development projects of Takara Bio Group ・ Gene Therapy py Target disease Location Business partner HSV TK Gene Therapy HSV-TK Leukemia Japan The National Cancer Center TCR Gene Therapy Esophageal cancer Japan Mie University School of Med
Slide 13: Strategies of Functional Foods Business and Basic Business Strategy
Ⅳ． Strategies of Functional Foods Business p25 Working hard to ensure that it will become our growth business in the future. future Takara Healthcare Healthcare, by utilizing Takara Bio’s unique, cutting-edge technologies ＋ the marketing and sales know-how of Takara Shuzo Finding the function of tra
Slide 14: Forward-Looking Statements
Forward--Looking Statements Forward p27 Statements in this document, other than those based on historical fact, concerning the current plans, prospects, strategies and expectations of the Company and its Group represent forecasts of future results. While such statements are based on the conclusions